Sam McGuckin

Sam McGuckin currently serves as the Head of Deviation Management at Lonza, overseeing the Deviation Management team at BioAtrium, a joint venture with Sanofi focused on large-scale mammalian biologics. Responsibilities include managing Deviations and CAPAs processes within the Quality Management System. Previously, Sam held the position of QA Manager at BioAtrium AG, ensuring compliant production of Monoclonal Antibodies. Additionally, experience includes roles as a Senior QA Specialist at Bristol-Myers Squibb, a Senior QA Associate at Amgen, and a QA Analyst at Helsinn Group, with a strong emphasis on cGMP compliance and quality assurance processes. Sam holds a Bachelor's degree in Pharmaceutical Healthcare from Technological University Dublin and a Master's degree in Mechanical Engineering from Dublin City University.